Every year, an estimated one million Americans participate in clinical trials to help researchers gather important information about the benefits and risks of new drugs and treatment methods. In recent surveys, the majority of these participants reported receiving excellent care and viewed their participation as a positive experience. Thanks to patients enrolled in clinical trials, researchers have been able to identify new and effective treatments for various types of cancer. These treatments have the potential to become the new standard of care offered to future patients.

ACRIN Study Participation

You are being asked to take part in this study because you have been diagnosed with prostate cancer and have enrolled in a study designed by Phillip Febbo, MD, a cancer researcher at Duke University. As part of this study you are receiving the drug dasatinib for your treatment.

The ACRIN study is evaluating an imaging test called a PET scan using the tracer drug 18F-fluoride. Twenty-four participants who are receiving dasatinib in Dr. Febbo’s study will also be enrolled in the ACRIN imaging study.

Why Is This Study Being Done?

The purpose of this study is to learn if the images provided by an 18F-fluoride PET scan can help doctors determine if the dasatinib is making any changes to normal bone or diseased bone. The information gained from the 18F-fluoride PET scan will be compared to other standard ways doctors evaluate the effectiveness of a cancer therapy drug. They hope to learn if the images from 18F-fluoride PET scan provide doctors with better information for identifying bone cancer.

Principal Investigators

Study Chair
Evan Y. Yu, M.D.
Seattle Cancer Care Alliance
Seattle, WA

Study Co-Chair
David A. Mankoff, M.D., Ph.D.
Seattle Cancer Care Alliance
Seattle, WA

Study Co-Chair
Fergus Coakley, M.D.
University of California San Francisco
San Francisco CA

Administrative Headquarters
American College of Radiology Imaging Network
1818 Market Street, Suite 1600
Philadelphia, PA 19103
(215) 574-3183

Local Contact

Funded by the National Cancer Institute

www.acrin.org
How long will I be in the study?

You will be involved with this study's imaging procedures for about 16 to 18 weeks. Each PET imaging visit will require about two to three hours of your time.

In addition, study doctors will review your medical records for up to 5 years to compare the results of the PET scan with the course of your cancer. The 18F-fluoride PET scans in this study will be taken before and after your dasatinib treatment.

What are the side effects of the study?

All participants will be carefully watched for any side effects as a result of the 18F-fluoride PET scan. Any side effects are usually mild. Talk to your doctor or nurse about any possible side effects at your initial consultation.

Are there benefits to taking part in the study?

This is not a treatment study and you are not expected to receive any direct medical benefits from your participation. The information learned from this study may lead to better treatment in the future for patients with prostate cancer.

Will I Have To Pay For Anything?

Taking part in this study will not add costs to you or your insurance company. Many of the tests and procedures performed as a part of this study are routine for patients with prostate cancer and will be charged to your insurance company in the usual manner. You may be responsible for co-payments and deductibles that are standard for your insurance coverage. ACRIN will pay for the two PET scans with 18F-fluoride as part of the study.